AAAAAA

   
Results: 1-9 |
Results: 9
Frequent demonstration of human herpesvirus 8 (HHV-8) in bone marrow biopsy samples from Turkish patients with multiple myeloma (MM)
Authors: Beksac, M Ma, M Akyerli, C DerDanielian, M Zhang, L Liu, J Arat, M Konuk, N Koc, H Ozcelik, T Vescio, R Berenson, JR
Citation: M. Beksac et al., Frequent demonstration of human herpesvirus 8 (HHV-8) in bone marrow biopsy samples from Turkish patients with multiple myeloma (MM), LEUKEMIA, 15(8), 2001, pp. 1268-1273
Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: Results of a multicenter randomized controlled trial
Authors: Stewart, AK Vescio, R Schiller, G Ballester, O Noga, S Rugo, H Freytes, C Stadtmauer, E Tarantolo, S Sahebi, F Stiff, P Meharchard, J Schlossman, R Brown, R Tully, H Benyunes, M Jacobs, C Berenson, R White, M DiPersio, J Anderson, KC Berenson, J
Citation: Ak. Stewart et al., Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: Results of a multicenter randomized controlled trial, J CL ONCOL, 19(17), 2001, pp. 3771-3779
The role of nuclear factor-kappa B in the biology and treatment of multiple myeloma
Authors: Berenson, JR Ma, HM Vescio, R
Citation: Jr. Berenson et al., The role of nuclear factor-kappa B in the biology and treatment of multiple myeloma, SEMIN ONCOL, 28(6), 2001, pp. 626-633
A phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease
Authors: Berenson, JR Vescio, R Henick, K Nishikubo, C Rettig, M Swift, RA Conde, F Von Teichert, JM
Citation: Jr. Berenson et al., A phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease, CANC CYTOP, 91(1), 2001, pp. 144-154
A phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease
Authors: Berenson, JR Vescio, R Henick, K Nishikubo, C Rettig, M Swift, RA Conde, F Von Teichert, JM
Citation: Jr. Berenson et al., A phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease, CANCER, 91(1), 2001, pp. 144-154
Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group
Authors: von Pawel, J von Roemeling, R Gatzemeier, U Boyer, M Elisson, LO Clark, P Talbot, D Rey, A Butler, TW Hirsh, V Olver, I Bergman, B Ayoub, J Richrdson, G Dunlop, D Arcenas, A Vescio, R Viallet, J Treat, J
Citation: J. Von Pawel et al., Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group, J CL ONCOL, 18(6), 2000, pp. 1351-1359
Cytomegalovirus infection following transplantation of autologous CD34-selected progenitor cells
Authors: Schiller, GJ Vescio, R Berenson, J
Citation: Gj. Schiller et al., Cytomegalovirus infection following transplantation of autologous CD34-selected progenitor cells, BLOOD, 96(3), 2000, pp. 1194-1194
Autologous transplantation - Purging and the impact of minimal residual disease
Authors: Vescio, R Berenson, J
Citation: R. Vescio et J. Berenson, Autologous transplantation - Purging and the impact of minimal residual disease, HEMAT ONCOL, 13(5), 1999, pp. 969
Multicenter phase III trial to evaluate CD34(+) selected versus unselectedautologous peripheral blood progenitor cell transplantation in multiple myeloma
Authors: Vescio, R Schiller, G Stewart, AK Ballester, O Noga, S Rugo, H Freytes, C Stadtmauer, E Tarantolo, S Sahebi, F Stiff, P Meharchard, J Schlossman, R Brown, R Tully, H Benyunes, M Jacobs, C Berenson, R DiPersio, J Anderson, K Berenson, J
Citation: R. Vescio et al., Multicenter phase III trial to evaluate CD34(+) selected versus unselectedautologous peripheral blood progenitor cell transplantation in multiple myeloma, BLOOD, 93(6), 1999, pp. 1858-1868
Risultati: 1-9 |